NO983141L - Antigene peptider - Google Patents

Antigene peptider

Info

Publication number
NO983141L
NO983141L NO983141A NO983141A NO983141L NO 983141 L NO983141 L NO 983141L NO 983141 A NO983141 A NO 983141A NO 983141 A NO983141 A NO 983141A NO 983141 L NO983141 L NO 983141L
Authority
NO
Norway
Prior art keywords
antigenic peptides
antigenic
peptides
Prior art date
Application number
NO983141A
Other languages
English (en)
Other versions
NO313834B1 (no
Inventor
Gustav Gaudernack
Jon Amund Eriksen
Marianne Klemp Gjertsen
Mona Moeller
Ingvil Saeterdal
Stein Saeboee-Larsen
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO983141(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/743,281 priority Critical patent/US7030211B1/en
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO19983141A priority patent/NO313834B1/no
Priority to PCT/NO1999/000220 priority patent/WO2000002581A1/en
Priority to PL345541A priority patent/PL203815B1/pl
Priority to EP20030075681 priority patent/EP1362597B2/en
Priority to DE69942072T priority patent/DE69942072D1/de
Priority to AT03075681T priority patent/ATE458494T1/de
Priority to CA 2336743 priority patent/CA2336743C/en
Priority to PT99928238T priority patent/PT1093381E/pt
Priority to EP99928238A priority patent/EP1093381B2/en
Priority to EP10183808.4A priority patent/EP2316476B1/en
Priority to DE1999610580 priority patent/DE69910580T3/de
Priority to AU45340/99A priority patent/AU756094B2/en
Priority to EP10154215.7A priority patent/EP2258383B1/en
Priority to DK99928238T priority patent/DK1093381T4/da
Priority to CZ20010037A priority patent/CZ303215B6/cs
Priority to ES03075681.1T priority patent/ES2341170T5/es
Priority to CA 2748996 priority patent/CA2748996A1/en
Priority to PT03075681T priority patent/PT1362597E/pt
Priority to ES99928238T priority patent/ES2200526T5/es
Priority to JP2000558840A priority patent/JP4618657B2/ja
Priority to DK03075681T priority patent/DK1362597T3/da
Priority to HU0104889A priority patent/HU230007B1/hu
Priority to CNB998099546A priority patent/CN100376290C/zh
Priority to AT99928238T priority patent/ATE247484T1/de
Priority to ARP990103374 priority patent/AR020601A1/es
Priority to TW88115173A priority patent/TWI261617B/zh
Publication of NO983141L publication Critical patent/NO983141L/no
Priority to HK02100577.9A priority patent/HK1039068B/zh
Publication of NO313834B1 publication Critical patent/NO313834B1/no
Priority to US11/332,378 priority patent/US7794723B2/en
Priority to CY101100364T priority patent/CY1109978T1/el
Priority to ARP100102596 priority patent/AR077576A2/es
Priority to JP2010177870A priority patent/JP5491315B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19983141A 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt NO313834B1 (no)

Priority Applications (32)

Application Number Priority Date Filing Date Title
US09/743,281 US7030211B1 (en) 1998-07-08 1990-06-30 Antigenic peptides derived from telomerase
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt
AT99928238T ATE247484T1 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide
ES03075681.1T ES2341170T5 (es) 1998-07-08 1999-06-30 Péptidos antigénicos derivados de telomerasa
CA 2748996 CA2748996A1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
EP20030075681 EP1362597B2 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
DE69942072T DE69942072D1 (de) 1998-07-08 1999-06-30 Von der Telomerase abgeleitete antigene Peptide
AT03075681T ATE458494T1 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide
CA 2336743 CA2336743C (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
PT99928238T PT1093381E (pt) 1998-07-08 1999-06-30 Peptidos antigenicos derivados de telomerase
EP99928238A EP1093381B2 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
EP10183808.4A EP2316476B1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
DE1999610580 DE69910580T3 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide
AU45340/99A AU756094B2 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
EP10154215.7A EP2258383B1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
DK99928238T DK1093381T4 (da) 1998-07-08 1999-06-30 Antigene peptider afledt fra teleromerase
CZ20010037A CZ303215B6 (cs) 1998-07-08 1999-06-30 Antigenní peptidy odvozené od telomerázy
PCT/NO1999/000220 WO2000002581A1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
PL345541A PL203815B1 (pl) 1998-07-08 1999-06-30 Zastosowanie peptydu telomerazy, zastosowanie kwasu nukleinowego, sposób wytwarzania limfocytów T, specyficzny wobec telomerazy limfocyt T, kompozycja farmaceutyczna, zastosowanie kombinacji peptydu telomerazy i peptydu zdolnego do indukowania odpowiedzi komórek T na onkogen lub zmutowane białko lub peptyd supresji nowotworów
PT03075681T PT1362597E (pt) 1998-07-08 1999-06-30 Péptidos antigénicos derivados de telomerase
ES99928238T ES2200526T5 (es) 1998-07-08 1999-06-30 Peptidos antigenicos derivados de telomerasa.
JP2000558840A JP4618657B2 (ja) 1998-07-08 1999-06-30 テロメラーゼ由来抗原ペプチド
DK03075681T DK1362597T3 (da) 1998-07-08 1999-06-30 Antigene peptider, der er afledt af telomerase
HU0104889A HU230007B1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
CNB998099546A CN100376290C (zh) 1998-07-08 1999-06-30 来自端粒酶的抗原性肽
ARP990103374 AR020601A1 (es) 1998-07-08 1999-07-12 Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c
TW88115173A TWI261617B (en) 1998-07-08 1999-09-03 Antigenic peptides
HK02100577.9A HK1039068B (zh) 1998-07-08 2002-01-25 來自端粒酶的抗原性肽
US11/332,378 US7794723B2 (en) 1998-07-08 2006-01-17 Antigenic peptides derived from telomerase
CY101100364T CY1109978T1 (el) 1998-07-08 2010-04-23 Αντιγονικα πεπτιδια εξαγομενα απο τελομεραση
ARP100102596 AR077576A2 (es) 1998-07-08 2010-07-15 Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos
JP2010177870A JP5491315B2 (ja) 1998-07-08 2010-08-06 テロメラーゼ由来抗原ペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt

Publications (2)

Publication Number Publication Date
NO983141L true NO983141L (no) 2000-01-10
NO313834B1 NO313834B1 (no) 2002-12-09

Family

ID=19902234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt

Country Status (20)

Country Link
US (2) US7030211B1 (no)
EP (4) EP2258383B1 (no)
JP (2) JP4618657B2 (no)
CN (1) CN100376290C (no)
AR (2) AR020601A1 (no)
AT (2) ATE247484T1 (no)
AU (1) AU756094B2 (no)
CA (2) CA2336743C (no)
CY (1) CY1109978T1 (no)
CZ (1) CZ303215B6 (no)
DE (2) DE69910580T3 (no)
DK (2) DK1362597T3 (no)
ES (2) ES2341170T5 (no)
HK (1) HK1039068B (no)
HU (1) HU230007B1 (no)
NO (1) NO313834B1 (no)
PL (1) PL203815B1 (no)
PT (2) PT1362597E (no)
TW (1) TWI261617B (no)
WO (1) WO2000002581A1 (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
WO1998014592A2 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
DE69934426T2 (de) * 1998-10-29 2007-10-04 Whitehead Institute For Biomedical Research, Cambridge KREBSIMMUNTHERAPIE UND KREBSDIAGNOSE UNTER VERWENDUNG UNIVERSELLER TUMORASSOZIIERTER ANTIGENE EINSCHLIESSLICH hTERT
AU781376B2 (en) * 1999-04-09 2005-05-19 Biomira Inc. Telomerase-specific cancer vaccine
JP2004527449A (ja) 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
ES2527946T3 (es) * 2003-03-05 2015-02-02 Dendreon Corporation Composiciones y métodos que emplean polipéptidos de marco de lectura alternativa para el tratamiento de cáncer y enfermedades infecciosas
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
AU2007215501A1 (en) * 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
JP5207354B2 (ja) * 2008-03-12 2013-06-12 独立行政法人産業技術総合研究所 転写抑制ペプチド及びその遺伝子
HUE030984T2 (en) * 2008-06-16 2017-06-28 Mediolanum Farm S P A Antitumor immunotherapy
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
CN105106934A (zh) 2009-11-10 2015-12-02 急速制药公司 用于抑制细胞粘附至rgd结合位点或引导诊断剂或治疗剂至rgd结合位点的组合物和方法
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
EP2536830B1 (en) * 2010-02-16 2019-07-17 Ultimovacs AS Polypeptides
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
EP2707036A4 (en) 2011-05-09 2015-03-18 Allegro Pharmaceuticals Inc INTEGRIN RECEPTOR ANTAGONISTS AND METHOD FOR THEIR USE
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
CN104507489B (zh) * 2012-05-11 2016-07-13 杰姆维克斯&凯尔有限公司 用于预防和治疗类风湿性关节炎的组合物
EP3333180B1 (en) * 2012-05-11 2019-08-21 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
WO2014010971A1 (ko) * 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
KR102201430B1 (ko) * 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
CN107312759A (zh) * 2012-09-19 2017-11-03 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
EP3736282B1 (en) 2012-09-19 2023-06-21 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) * 2012-10-22 2014-04-09 南京工业大学 一种制备端粒酶多肽疫苗的方法
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
ES2716870T3 (es) * 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
KR102275912B1 (ko) * 2013-05-03 2021-07-12 주식회사 젬백스앤카엘 Hsp 발현 억제 펩티드 및 이를 포함하는 조성물
US10383926B2 (en) 2013-06-07 2019-08-20 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
ES2808076T3 (es) * 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
WO2015005723A1 (ko) * 2013-07-12 2015-01-15 주식회사 카엘젬백스 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
WO2015023132A1 (ko) * 2013-08-14 2015-02-19 주식회사 카엘젬백스 다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CN110755599A (zh) * 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
EP3072519B1 (en) * 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
KR102106757B1 (ko) * 2013-11-29 2020-05-06 주식회사 젬백스앤카엘 난소 동결 보존용 펩티드 및 이를 포함하는 조성물
EP3085380B1 (en) * 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
JP6466971B2 (ja) 2014-04-30 2019-02-06 ジェムバックス アンド カエル カンパニー，リミティド 臓器、組織又は細胞移植用組成物、キット及び移植方法
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
CN104031120B (zh) * 2014-05-29 2016-08-24 王凤羽 一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
KR102397510B1 (ko) * 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
KR102413243B1 (ko) * 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
EP3305802B1 (en) 2015-05-26 2021-05-12 Gemvax & Kael Co., Ltd. Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same
KR102638286B1 (ko) * 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20170054310A (ko) * 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN110392696B (zh) 2017-01-06 2020-09-11 优特力克斯有限公司 抗-人4-1bb抗体及其应用
US11771749B2 (en) 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
JP2020522479A (ja) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 個別化された癌ワクチンを作製する方法
US20200209241A1 (en) 2017-09-15 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
EP0765386B1 (en) 1994-06-14 2014-12-10 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
ES2184990T3 (es) * 1996-02-12 2003-04-16 Ml Lab Plc Nuevos metodos de vacunacion y vacunas para los mismos que comprenden un acido nucleico que codifica un primer epitope y un peptido que contiene un segundo epitope.
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
DE69733255T2 (de) * 1996-07-08 2006-01-19 Vivoxid Oy Bioabbaubares material mit hoher schlagzähigkeit
WO1998014592A2 (en) * 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants

Also Published As

Publication number Publication date
JP2002520293A (ja) 2002-07-09
DE69910580T2 (de) 2004-06-24
WO2000002581A1 (en) 2000-01-20
JP5491315B2 (ja) 2014-05-14
AR077576A2 (es) 2011-09-07
EP1362597B2 (en) 2014-06-25
EP1093381B1 (en) 2003-08-20
DE69942072D1 (de) 2010-04-08
HK1039068A1 (en) 2002-04-12
PT1362597E (pt) 2010-04-14
US7794723B2 (en) 2010-09-14
CN1313773A (zh) 2001-09-19
HK1039068B (zh) 2009-02-06
DE69910580D1 (de) 2003-09-25
EP2316476B1 (en) 2015-11-25
EP1362597B1 (en) 2010-02-24
PL345541A1 (en) 2001-12-17
ES2200526T5 (es) 2009-12-11
ES2341170T5 (es) 2014-09-09
EP2258383A3 (en) 2011-05-11
ES2200526T3 (es) 2004-03-01
AU756094B2 (en) 2003-01-02
EP1093381B2 (en) 2009-07-22
CA2336743C (en) 2011-10-11
HU230007B1 (en) 2015-04-28
TWI261617B (en) 2006-09-11
CA2336743A1 (en) 2000-01-20
DE69910580T3 (de) 2009-11-26
CY1109978T1 (el) 2014-09-10
DK1093381T4 (da) 2009-09-21
JP2010252810A (ja) 2010-11-11
NO313834B1 (no) 2002-12-09
JP4618657B2 (ja) 2011-01-26
EP1093381A1 (en) 2001-04-25
DK1093381T3 (da) 2003-09-08
DK1362597T3 (da) 2010-06-14
ATE458494T1 (de) 2010-03-15
AR020601A1 (es) 2002-05-22
US7030211B1 (en) 2006-04-18
PL203815B1 (pl) 2009-11-30
CZ303215B6 (cs) 2012-05-30
US20060106196A1 (en) 2006-05-18
EP2258383B1 (en) 2016-03-09
ATE247484T1 (de) 2003-09-15
CZ200137A3 (en) 2001-06-13
CA2748996A1 (en) 2000-01-20
EP2316476A3 (en) 2011-09-14
HUP0104889A2 (hu) 2002-04-29
HUP0104889A3 (en) 2004-04-28
PT1093381E (pt) 2004-01-30
ES2341170T3 (es) 2010-06-16
EP1362597A1 (en) 2003-11-19
CN100376290C (zh) 2008-03-26
AU4534099A (en) 2000-02-01
EP2316476A2 (en) 2011-05-04
EP2258383A2 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
NO983141L (no) Antigene peptider
NO982097D0 (no) Peptider
NO982098D0 (no) Peptider
NO20003303L (no) Vaksine
BR9711853A (pt) Vacinas
DK1042359T3 (da) k-Opioidreceptorpeptider
ATE394489T1 (de) Streptococcus antigene
NO985464D0 (no) Konsentrert antistoffpreparat
DE69727572D1 (de) Wässrige peptidzubereitung
DE69824918D1 (de) Sammler
ATE347600T1 (de) Gruppe b-streptococcus antigene
FI970168A (fi) Peptidejä
NO983849L (no) Peptidderivater
DE59807796D1 (de) Texturiermaschine
NO20005599L (no) Vaksine
DE69925271D1 (de) Angiostatin-bindendes protein
NO975938D0 (no) Anti-fedme proteiner
DE59801799D1 (de) Reinigungsgerät
DE59803807D1 (de) Reinigungsgerät
NO20012283D0 (no) Koblede peptider
NO20013933D0 (no) Peptider
NO996412D0 (no) Antigene peptider
ATA115898A (de) Taschenkettenrad
ATA93697A (de) Gasarmatur
ID23663A (id) Persiapan kaprolaktam

Legal Events

Date Code Title Description
MK1K Patent expired